Sanofi (SNY)

44.90
0.29 0.65
NYSE : Health Technology
Prev Close 44.61
Open 45.02
Day Low/High 44.76 / 45.30
52 Wk Low/High 37.43 / 46.25
Volume 1.36M
Avg Volume 1.62M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 114.00B
EPS 1.70
P/E Ratio 24.51
Div & Yield 1.20 (2.78%)

Latest News

Sanofi Q3 2018 Performance Confirms Return To Growth

Sanofi Q3 2018 Performance Confirms Return To Growth

PARIS , Oct. 31, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2018 Change Change at CER 9M 2018 Change Change at CER IFRS net sales reported €9,392m +3.

FDA Grants Priority Review For Sanofi's Dengue Vaccine Candidate

FDA Grants Priority Review For Sanofi's Dengue Vaccine Candidate

BRIDGEWATER, N.J.

Breakthroughs In Breast Cancer Research

Breakthroughs In Breast Cancer Research

BRIDGEWATER, N.J.

FDA Approves Asthsma Indication For Dupixent® (dupilumab)

FDA Approves Asthsma Indication For Dupixent® (dupilumab)

-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype

Canadians Are Invited To Join The Conversation: Raise Your Hand For Diabetes

Canadians Are Invited To Join The Conversation: Raise Your Hand For Diabetes

LAVAL, QC, Oct. 17, 2018 /CNW Telbec/ - Sanofi Canada is on a mission to raise awareness and money to help people living with diabetes, one of the leading causes of death and disability in Canada.

Dupixent® (dupilumab) Showed Positive Topline Results In Two Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps

Dupixent® (dupilumab) Showed Positive Topline Results In Two Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery

What To Do When You Can't Afford Your Chronic Disease Medication

What To Do When You Can't Afford Your Chronic Disease Medication

When Out-of-Pockets get too high, there are many programs to help, whether or not you have insurance

Keeping Women In STEM Careers: Looking To Data For Answers

Keeping Women In STEM Careers: Looking To Data For Answers

BRIDGEWATER, N.J.

Sanofi Aims To Topple The Flu As It Marks National Seniors Day With A Guinness World Record Attempt

Sanofi Aims To Topple The Flu As It Marks National Seniors Day With A Guinness World Record Attempt

Influenza has a significant human and economic impact due to the burden of illness and high number of hospitalizations.

FDA Approves Libtayo® (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

FDA Approves Libtayo® (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* Libtayo is the third anti-PD-1 approved in the U.S.

Sanofi US Named To Working Mother 2018 "100 Best Companies" List

Sanofi US Named To Working Mother 2018 "100 Best Companies" List

BRIDGEWATER, N.J.

National Meningitis Association Urges Parents To Get Their Teens The 16 Vaccine To Help Protect Against Meningococcal Meningitis

National Meningitis Association Urges Parents To Get Their Teens The 16 Vaccine To Help Protect Against Meningococcal Meningitis

Vaccination is the best defense against meningococcal disease, yet more than half of U.S. teens have missed the Centers for Disease Control and Prevention's recommended second dose of MenACWY at age 16(1)

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy

Cablivi™ (caplacizumab) Approved In Europe For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Cablivi™ (caplacizumab) Approved In Europe For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Nvidia, nvidia, NVIDIA. In non-Nvidia news, the market faces some serious threats in the back half of 2018. And hey, about Elon Musk's latest interview ...

Q2 2018 Performance Positions Sanofi For New Growth Phase

Q2 2018 Performance Positions Sanofi For New Growth Phase

PARIS, July 31, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.

Sanofi Ships First Flu Vaccines For 2018-2019 Season

Sanofi Ships First Flu Vaccines For 2018-2019 Season

Nearly 70 million doses to be manufactured this season

New Insights Revealed In National Survey Show More Advances Are Needed For The Type 1 Diabetes Community

New Insights Revealed In National Survey Show More Advances Are Needed For The Type 1 Diabetes Community

Endocrinologists and Adults with Type 1 Diabetes Struggle to Keep Blood Sugar within Recommended Range Yet Remain Hopeful and Optimistic About the Future of Disease Management

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CFBK, CLDT, SNY, VET Downgrades: ADNT, AOI, BVN Initiations: AMMA Read on to get TheStreet Quant Ratings' detailed report:

New England Journal Of Medicine Publishes Final Results From Innovative Phase 2 Study Showing Vaccines Can Reduce Rate Of Sustained TB Infections In Adolescents At High Risk

New England Journal Of Medicine Publishes Final Results From Innovative Phase 2 Study Showing Vaccines Can Reduce Rate Of Sustained TB Infections In Adolescents At High Risk

Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against Tuberculosis, the world's leading infectious disease killer

Sanofi To Further Accelerate Its Scientific Presence With The Opening Of A Global R&D Operations Hub In Chengdu, China

Sanofi To Further Accelerate Its Scientific Presence With The Opening Of A Global R&D Operations Hub In Chengdu, China

- Company invests €66 million in Chengdu, Sichuan province, China

Sanofi Presents Results From The First Head-to-head Study Comparing Toujeo® To Insulin Degludec

Sanofi Presents Results From The First Head-to-head Study Comparing Toujeo® To Insulin Degludec

- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Canadian Employers Underestimate The Proportion Of Their Workforce With A Chronic Condition And Its Impact

Canadian Employers Underestimate The Proportion Of Their Workforce With A Chronic Condition And Its Impact

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Three-quarters of employers are worried about the impact of unmanaged chronic disease Two-thirds (66%) of Canadian employees would consent to receive personalized information based on their own benefits claims...

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

TheStreet Quant Rating: A- (Buy)